Cancer of the Prostate Clinical Trial
Official title:
A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. Post Study 5-year Follow-up
Verified date | March 2021 |
Source | Steba Biotech S.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is an open observational extended follow-up study of patients originally randomized into TOOKAD® Soluble VTP therapy or active surveillance (control group). Additional 60-month follow-up study
Status | Completed |
Enrollment | 374 |
Est. completion date | June 3, 2020 |
Est. primary completion date | June 3, 2020 |
Accepts healthy volunteers | |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All subjects originally randomized in study CLIN1001 PCM301 are included in this follow-up study. As a reminder, they all met the following criteria at entry (from the original protocol): 1. Low risk prostate cancer diagnosed using one trans-rectal ultrasound guided biopsy (TRUS) using from 10 to 24 cores, within 12 months of enrolment and showing the following: - Gleason 3 + 3 prostate adenocarcinoma as a maximum, - Two (2) to three (3) cores positive for cancer. Patients with only one positive core can be included provided they have at least 3 mm of cancer core length. - A maximum cancer core length of 5 mm in any core. 2. Cancer clinical stage up to T2a (pathological or radiological up to T2c disease permitted). 3. Serum prostate specific antigen (PSA) of 10 ng/mL or less. 4. Prostate volume equal or greater than 25 cc and less than 70 cc. 5. Male subjects aged 18 years or older. Exclusion Criteria: - As a reminder, all subjects originally randomized did not met the following criteria at entry (from the original protocol): 1. Unwillingness to accept randomization to either of the two arms of the study. 2. Any prior or current treatment for prostate cancer, including surgery, radiation therapy (external or brachytherapy) or chemotherapy. 3. Any surgical intervention for benign prostatic hypertrophy. 4. Life expectancy less than 10 years. 5. Any condition or history of illness or surgery that may pose an additional risk to men undergoing the VTP procedure. 6. Participation in another clinical study or recipient of an investigational product within 1 month of study entry. 7. Subject unable to understand the patient's information document, to give consent or complete the study tasks. Subject in custody and or in residence in a nursing home or rehabilitation facility. 8. Contra-indication to MRI (e.g., pacemaker, history of allergic reaction to gadolinium), or factors excluding accurate reading of pelvic MRI (e.g., hip prosthesis). |
Country | Name | City | State |
---|---|---|---|
Finland | Department of Urology-Tampere University Hospital- | Tampere | |
France | Centre Hospitalier Universitaire (CHU) | Angers | |
France | CHRU Hopital Jean Minjoz | Besançon | |
France | Site Médipole | Cabestany | |
France | Polyclinique Sévigné | Cesson Sévigné | |
France | Hôpital Claude Huriez | Lille | |
France | Hôpital La Conception | Marseille | |
France | Hôpital Tenon | Paris | |
France | Hôpital Cochin | Paris Cedex 14 | |
France | Institut Mutualiste Montsouris (IMM) | Paris Cedex 14 | |
France | Centre Hospitalier Universitaire Lyon Sud | Pierre-Bénite | |
France | CHU Pontchaillou | Rennes | |
France | Clinique Urologique Nantes | Saint Herblain | |
Germany | Marien Krankenahaus GmbH | Bergisch Gladbach | |
Germany | ATURO-Gemeinschaftspraxis für Urologie und Andrologie | Berlin-Wilmersdorf | |
Germany | Klinikum Braunschweig | Braunschweig | |
Germany | Universitätsklinikum "Carl Gustav Carus" der Technischen Universität | Dresden | |
Germany | Urologische Gemeinschaftspraxis | Emmendingen | |
Germany | Martini-Klinik am UKE Hamburg-Eppendorf Prostate Cancer Center | Hamburg | |
Germany | Vinzenz Krankenhaus - Department of Urology | Hannover | |
Germany | SLK-Kliniken Heilbronn GmbH | Heilbronn | |
Germany | University Hospital Schleswig-Holstein | Kiel | |
Germany | Ludwig-Maximilians-Universität München | Munich | |
Germany | Urologie 24 | Nuremberg | |
Italy | Osp. S. Giov. Battista Molinette-Dipartimento di Discipline Medico-Chirurgiche Urologia | Torino | |
Netherlands | Netherlands Cancer Institute | Amsterdam | |
Netherlands | Catharina Ziekenhuis | Eindhoven | |
Spain | Hospital Universitario de A Coruña | A Coruña | |
Spain | Department of Urology-Hospital Clinic, University of Barcelona | Barcelona | |
Spain | Complejo Hospitalario Regional Virgen Del Rocio-Department Urology | Sevilla | |
Spain | Instituto Valenciano de Oncologia | Valencia | |
Sweden | Dept of Urology-University Hospital- | Malmö | |
United Kingdom | Kings College Hospital (KCH) | London | |
United Kingdom | University College London Hospital (UCLH) | London | |
United Kingdom | Oxford John Radcliffe Hospital Trust | Oxford | |
United Kingdom | Royal Hallamshire Hospital | Sheffield |
Lead Sponsor | Collaborator |
---|---|
Steba Biotech S.A. | ICON plc, International Drug Development Institute |
Finland, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease progression | Progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer in men initially randomized to TOOKAD® Soluble VTP compared to men originally randomized on active surveillance. | Over the 5 years of follow up | |
Primary | Other prostate cancer therapy | Use of other prostate cancer therapy: radical therapy (surgery, radiotherapy, cryotherapy, ultrasound therapy), hormonal therapy or chemotherapy or any therapy indicated for the treatment of prostate cancer in the countries of the study. | Over the 5 years of follow up | |
Primary | Prostate cancer-related death. | Any death related to Prostate cancer | Over the 5 years of follow up | |
Secondary | Absence of cancer | The proportion of absence of cancer at biopsy (when available) | Over the 5 years of follow up | |
Secondary | Radical therapy | The rate of prostate cancer radical therapy; | Over the 5 years of follow up | |
Secondary | Cancer burden | The total cancer burden in the prostate | Over the 5 years of follow up | |
Secondary | Urinary incontinence | The description of incontinence in terms of mean, median, SD, inter-quartile ranges, min-max | Over the 5 years of follow up | |
Secondary | Erectile dysfunction | The description of erectile dysfunction in terms of mean, median, SD, inter-quartile ranges, min-max | Over the 5 years of follow up | |
Secondary | Urethral stenosis | The rate of urethral stenosis | Over the 5 years of follow up | |
Secondary | Prostate cancer complication | The rate of severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death | Over the 5 years of follow up | |
Secondary | Patients Questionnaires Quality of life | Overal Quality of Life will be recorded for potential utility and descriptives studies | Over the 5 years of follow up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03653819 -
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
|
N/A | |
Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06363266 -
A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers
|
N/A | |
Active, not recruiting |
NCT02003924 -
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
|
Phase 3 | |
Completed |
NCT00643617 -
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
|
N/A | |
Completed |
NCT00844792 -
Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Completed |
NCT01303705 -
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
|
Phase 1 | |
Completed |
NCT02578940 -
Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
|
Phase 3 | |
Completed |
NCT04057859 -
PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness Training
|
||
Completed |
NCT00564928 -
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT02958787 -
Vessel Sparing Prostate Radiation Therapy
|
Phase 2 | |
Completed |
NCT01897207 -
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05241236 -
MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
|
||
Active, not recruiting |
NCT03939689 -
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
|
Phase 2 | |
Completed |
NCT02274350 -
The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects
|
N/A | |
Completed |
NCT00744549 -
Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
|
Phase 2 | |
Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02212548 -
Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose
|
N/A | |
Active, not recruiting |
NCT03238170 -
MR-simulation in Radiotherapy for Prostate Cancer
|
N/A |